Increased Body Mass Index Is Associated with Earlier Time to Loss of Response to Infliximab in Patients with Inflammatory Bowel Disease

Predictors of dose escalation of adalimumab in a prospective cohort of Crohn’s disease patients

(2011) E. Bultman et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review

(2011) Vincent Billioud et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Direct Medical Cost of Managing IBD Patients: A Canadian Population-based Study

(2011) Charles N. Bernstein et al.   INFLAMMATORY BOWEL DISEASES

Body mass index and clinical response to infliximab in rheumatoid arthritis

(2010) Ruth Klaasen et al.   ARTHRITIS AND RHEUMATISM

The Placebo Response Rate in Irritable Bowel Syndrome and Inflammatory Bowel Disease

(2010) Bruce E. Sands   DIGESTIVE DISEASES

Prevalence and epidemiology of overweight and obesity in children with inflammatory bowel disease 12

(2010) Millie D. Long et al.   INFLAMMATORY BOWEL DISEASES

Association Between Adiposity in Midlife and Older Age and Risk of Diabetes in Older Adults

(2010) Mary L. Biggs   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Top-down therapy for IBD: rationale and requisite evidence

(2010) Geert R. D'Haens   Nature Reviews Gastroenterology & Hepatology

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease

(2009) Ioannis E. Koutroubakis et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort

(2008) F Schnitzler et al.   GUT

Effect of anti-tumor necrosis factor-α therapies on body mass index in patients with psoriasis

(2008) R SARACENO et al.   PHARMACOLOGICAL RESEARCH